Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study

Summary

Background Osimertinib is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, the occurrence rate of osimertinib-induced interstitial lung disease (ILD) is particularly high in Japanese patients and little information on subsequent cancer treatment options after recovery from osimertinib-induced ILD is currently available. Thus, this study aims to determine the safety and efficacy of afatinib for the treatment of NSCLC following osimertinib-induced ILD. Methods We retrospectively investigated the clinical courses of all NSCLC patients with EGFR mutations at our facility between August 2018 and September 2019, who received osimertinib as first-line treatment and were subsequently treated with afatinib after developing osimertinib-induced ILD. Results Forty-two patients received osimertinib treatment at our facility during the study period, and four patients received afatinib after developing osimertinib-induced ILD. All events of ILD improved either spontaneously or with steroid therapy before the initiation of afatinib. For the four patients who were retrospectively reviewed, the overall response rate to afatinib therapy was 75%, and the disease control rate was 100%. During the study period, no ILD recurrence was observed in any of the four patients. Conclusions According to our study findings, afatinib treatment after osimertinib-induced ILD is considered safe and effective and it can be used as one of the treatment options for NSCLC following osimertinib-induced ILD.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Mok TS, Wu Y-L, Ahn M-J et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640

    CAS  Article  Google Scholar 

  2. 2.

    Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    CAS  Article  Google Scholar 

  3. 3.

    Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50

    CAS  Article  Google Scholar 

  4. 4.

    Ohe Y, Imamura F, Nogami N et al (2019) Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol 49:29–36

    Article  Google Scholar 

  5. 5.

    Kato T, Yoshioka H, Okamoto I et al (2015) Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci 106:1202–1211

    CAS  Article  Google Scholar 

  6. 6.

    Camus P, Fanton A, Bonniaud P et al (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326

    Article  Google Scholar 

  7. 7.

    Itano J, Higo H, Ohashi K et al (2020) Successful re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review. Intern Med 59:823–828

    Article  Google Scholar 

  8. 8.

    Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549–2556

    CAS  Article  Google Scholar 

  9. 9.

    Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105:1584–1590

    CAS  Article  Google Scholar 

  10. 10.

    Miyauchi E, Ichinose M, Inoue A (2017) Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease. J Thorac Oncol 12:e59–e61

    Article  Google Scholar 

  11. 11.

    Nagasaka M, Gadgeel SM (2018) Retreatment with osimertinib following pneumonitis. Clin Lung Cancer 19:e53–e55

    Article  Google Scholar 

  12. 12.

    Kiriu T, Tamura D, Tachihara M et al (2018) Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med 57:91–95

    Article  Google Scholar 

  13. 13.

    Satoh S, Shiroyama T, Tamiya M et al (2017) Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. Respir Med Case Rep 23:68–70

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Schoenfeld AJ, Arbour KC, Rizvi H et al (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30:839–844

    CAS  Article  Google Scholar 

  15. 15.

    Koyama S, Omura T, Yonezawa A et al (2015) Gefitinib and erlotinib lead to phosphorylation of eukaryotic initiation factor 2 alpha independent of epidermal growth factor receptor in A549 cells. PLoS One 10:e0136176

    Article  Google Scholar 

  16. 16.

    Lee H, Lee HY, Sun JM et al (2018) Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol 13:1106–1112

    Article  Google Scholar 

  17. 17.

    Noonan SA, Sachs PB, Camidge DR (2016) Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 11:2253–2258

    Article  Google Scholar 

  18. 18.

    Yokoyama T, Yoshioka H, Fujimoto D et al (2019) A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer 135:175–180

    Article  Google Scholar 

  19. 19.

    Kashiwabara K, Semba H, Fujii S et al (2016) Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respir Investig 54:468–472

    Article  Google Scholar 

  20. 20.

    Schuler M, Wu YL, Hirsh V et al (2016) First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11:380–390

    Article  Google Scholar 

  21. 21.

    Paz-Ares L, Tan EH, O’Byrne K et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28:270–277

    CAS  Article  Google Scholar 

  22. 22.

    Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Shingo Nasu designed the study and wrote the initial draft of the manuscript. Shingo Nasu, Hidekazu Suzuki contributed to analysis and interpretation of our data and assisted in the preparation of the manuscript. All other authors have contributed to the data collection and interpretation and reviewed the manuscript. All authors approved the version of the manuscript finally and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Shingo Nasu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Institutional review board (IRB) approval for this study was obtained from the Medical Research Ethics Committee of Osaka Habikino Medical Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was waived by the IRB because of the retrospective nature of this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nasu, S., Suzuki, H., Shiroyama, T. et al. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study. Invest New Drugs (2020). https://doi.org/10.1007/s10637-020-00963-w

Download citation

Keywords

  • Afatinib
  • Drug-induced interstitial lung disease
  • Osimertinib
  • Epidermal growth factor receptor mutation